Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $61.07 (market cap $44.49B), while Vertex Pharmaceuticals Incorporated trades at $510.77 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.9× JPMorgan Nasdaq Equity Premium Income ETF's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 65 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| JEPQ | VRTX | |
|---|---|---|
Market Cap | $44.49B | $127.55B |
Volume | 5,681,789 | 1,487,944 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $557.96 |
52-Week Low | $53.77 | $407.37 |
Typical Hold Time | 65 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $61.03, down 0.39% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The ETF maintains strong income generation through its covered-call strategy, with recent dividends ranging from $0.57 to $0.70 per share. Financial media coverage highlights JEPQ's 11% estimated annualized yield and suitability for retirement income, though analysts note the trade-off between high current income and limited price appreciation potential.
JEPQ offers exceptional current income for investors seeking monthly cash flow, with its covered-call strategy performing well in volatile markets. However, the ETF faces risks from market volatility dependence and potential principal erosion if yield chasing outweighs total return considerations. Institutional interest remains strong, with Envestnet increasing its position by 8.2% recently.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
